P53 interacts with RNA polymerase II through its core domain and impairs Pol II processivity in vivo

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Kim, Sunyoung ^a   Balakrishnan, Sri Kripa ^a   Gross, David S ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZAURACIL; PROTEIN P53; RNA POLYMERASE II; SERINE;

ARTICLE; CONTROLLED STUDY; DNA BINDING; ENZYME INHIBITION; GENE MUTATION; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN RNA BINDING; REPORTER GENE; RNA TRANSLATION; YEAST CELL; CHEMISTRY; GENETICS; METABOLISM; PHOSPHORYLATION; POINT MUTATION; PROTEIN BINDING; SACCHAROMYCES CEREVISIAE;

PHOSPHORYLATION; POINT MUTATION; PROTEIN BINDING; RNA POLYMERASE II; SACCHAROMYCES CEREVISIAE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79961141113     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022183     Document Type: Article

References (40)

1. Zilfou JT, Lowe SW, (2009) Tumor Suppressive Functions of p53. Cold Spring Harb Perspect Biol 1: a001883.
2. Friedman PN, Chen X, Bargonetti J, Prives C, (1993) The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci U S A 90: 3319-3323.
3. Imbriano C, Gurtner A, Cocchiarella F, Di Agostino S, Basile V, et al. (2005) Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol 25: 3737-3751.
4. Ho WC, Fitzgerald MX, Marmorstein R, (2006) Structure of the p53 core domain dimer bound to DNA. J Biol Chem 281: 20494-20502.
5. Candau R, Scolnick DM, Darpino P, Ying CY, Halazonetis TD, et al. (1997) Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene 15: 807-816.
6. Unger T, Nau MM, Segal S, Minna JD, (1992) p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 11: 1383-1390.
7. Jenkins LM, Yamaguchi H, Hayashi R, Cherry S, Tropea JE, et al. (2009) Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry 48: 1244-1255.
8. Espinosa JM, Verdun RE, Emerson BM, (2003) p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 12: 1015-1027.
9. Laptenko O, Prives C, (2006) Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 13: 951-961.
10. An W, Kim J, Roeder RG, (2004) Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117: 735-748.
11. McKinney K, Mattia M, Gottifredi V, Prives C, (2004) p53 linear diffusion along DNA requires its C terminus. Mol Cell 16: 413-424.
12. Merrill GF, Dowell P, Pearson GD, (1999) The human p53 negative regulatory domain mediates inhibition of reporter gene transactivation in yeast lacking thioredoxin reductase. Cancer Res 59: 3175-3179.
13. Bode AM, Dong Z, (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805.
14. Bullock AN, Fersht AR, (2001) Rescuing the function of mutant p53. Nat Rev Cancer 1: 68-76.
15. Wong KB, DeDecker BS, Freund SM, Proctor MR, Bycroft M, et al. (1999) Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A 96: 8438-8442.
16. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, et al. (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303: 1010-1014.
17. Cho Y, Gorina S, Jeffrey PD, Pavletich NP, (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355.
18. Bullock AN, Henckel J, Fersht AR, (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19: 1245-1256.
19. Sigal A, Rotter V, (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788-6793.
20. Peng Y, Chen L, Li C, Lu W, Chen J, (2001) Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 276: 40583-40590.
21. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH, (1998) The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 18: 1517-1524.
22. Barsotti AM, Prives C, (2009) Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 28: 4295-4305.
23. Gridasova AA, Henry RW, (2005) The p53 tumor suppressor protein represses human snRNA gene transcription by RNA polymerases II and III independently of sequence-specific DNA binding. Mol Cell Biol 25: 3247-3260.
24. Arndt KM, Kane CM, (2003) Running with RNA polymerase: eukaryotic transcript elongation. Trends Genet 19: 543-550.
25. Di Lello P, Jenkins LM, Jones TN, Nguyen BD, Hara T, et al. (2006) Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell 22: 731-740.
26. Dvir A, Conaway RC, Conaway JW, (1997) A role for TFIIH in controlling the activity of early RNA polymerase II elongation complexes. Proc Natl Acad Sci U S A 94: 9006-9010.
27. Shinobu N, Maeda T, Aso T, Ito T, Kondo T, et al. (1999) Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53. J Biol Chem 274: 17003-17010.
28. Kim J, Guermah M, Roeder RG, (2010) The human PAF1 complex acts in chromatin transcription elongation both independently and cooperatively with SII/TFIIS. Cell 140: 491-503.
29. Balakrishnan SK, Gross DS, (2008) The tumor suppressor p53 associates with gene coding regions and co-traverses with elongating RNA polymerase II in an in vivo model. Oncogene 27: 2661-2672.
30. Saunders A, Core LJ, Lis JT, (2006) Breaking barriers to transcription elongation. Nat Rev Mol Cell Biol 7: 557-567.
31. Mason PB, Struhl K, (2005) Distinction and relationship between elongation rate and processivity of RNA polymerase II in vivo. Mol Cell 17: 831-840.
32. Riles L, Shaw RJ, Johnston M, Reines D, (2004) Large-scale screening of yeast mutants for sensitivity to the IMP dehydrogenase inhibitor 6-azauracil. Yeast 21: 241-248.
33. Morillo-Huesca M, Vanti M, Chavez S, (2006) A simple in vivo assay for measuring the efficiency of gene length-dependent processes in yeast mRNA biogenesis. FEBS J 273: 756-769.
34. Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S, (2002) HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem 277: 33922-33929.
35. Erdeniz N, Mortensen UH, Rothstein R, (1997) Cloning-free PCR-based allele replacement methods. Genome Res 7: 1174-1183.
36. Venturi CB, Erkine AM, Gross DS, (2000) Cell cycle-dependent binding of yeast heat shock factor to nucleosomes. Mol Cell Biol 20: 6435-6448.
37. Zhao J, Herrera-Diaz J, Gross DS, (2005) Domain-wide displacement of histones by activated heat shock factor occurs independently of Swi/Snf and is not correlated with RNA polymerase II density. Mol Cell Biol 25: 8985-8999.
38. Qiu H, Hu C, Hinnebusch AG, (2009) Phosphorylation of the Pol II CTD by KIN28 enhances BUR1/BUR2 recruitment and Ser2 CTD phosphorylation near promoters. Mol Cell 33: 752-762.
39. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B, (1992) Definition of a consensus binding site for p53. Nat Genet 1: 45-49.
40. Lee S, Gross DS, (1993) Conditional silencing: The HMRE mating-type silencer exerts a rapidly reversible position effect on the yeast HSP82 heat shock gene. Mol Cell Biol 13: 727-738.